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Abstract
Purpose Our aim was to describe the adverse drug reactions
(ADRs) detected following increased education about phar-
macovigilance and drug toxicity in children in Camagüey
Province, Cuba.
Methods Over a period of 24 months (January 2009 to
December 2010), all reports of suspected ADRs in children
to the Provincial Pharmacovigilance Centre in Camagüey
Province were analysed. ADRs were classified in relation to
causality and severity.
Results There were 533 reports involving suspected ADRs
in children in the period. Almost one third of the reports
received were classified as moderate (155, 29%) or severe
(10, 2%). There was one fatality in association with the use
of ceftriaxone. Vaccines and antibiotics were responsible for
most of the ADR reports (392, 74%) and for all ten severe
ADRs. After an intensive educational package, both within
the community and the Children’s Hospital, the number of
reports increased from 124 in 2008 to 161 in 2009 and 372
in 2010. This was equivalent to a reporting rate of 879 and
2,031 reports per million children per year for 2009 and
2010, respectively.
Conclusions The incidence of ADRs in children Camagüey
Province, Cuba, is greater than previously reported. An
educational intervention about pharmacovigilance and drug
toxicity in children can improve the reporting of ADRs.
Introduction
Adverse drug reactions (ADRs) are a significant problem in
children, and it is widely accepted that most are unreported.
We previously demonstrated an ADR reporting rate of 634
per million children per year in Cuba [1]. Others have
described 226 reports per million children per year in Swe-
den [2]. Systematic reviews have shown that almost one in
ten children in hospital will experience an ADR [3, 4].
Although the majority of ADRs are mild, a small number
are severe [5, 6]. Cuba has an excellent healthcare system,
which includes an extensive primary health care system [7].
Following assessment in primary care, children may be seen
in either polyclinics or in children’s hospitals. It also has a
National Pharmacovigilance Programme, which was estab-
lished in Cuba in 1996 [8]. Suspected ADRs are reported to
provinces, which then forward them on to the National
Coordinating Centre [8]. Camagüey Province has a particu-
lar interest in children who experience ADRs.
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Cuba.PharmacovigilanceWe described the ADRs detected in children in Cama-
güey Province in 2008 [1]. Although we demonstrated an
ADR reporting rate of 634 per million children per year in
Cuba, we recognised that this figure was likely to be a
significant underestimate of the true rate of ADRs. We
received very few reports from the Children’s Hospital in
Camagüey. Additionally, the Provincial Pharmacovigilance
Centre only received reports from the Municipality of
Camagüey and not from the 12 other municipalities within
the province. An educational package about pharmacovigi-
lance and drug toxicity was targeted at health professionals
in the province who were involved in the care of children
either within the community or in hospital. This involved
educational meetings, group discussion of clinical cases
with suspected ADRs, individualised teaching and emails
with safety alerts or specific articles focussing on pharma-
covigilance/drug toxicity. The educational package recog-
nised that different health professionals had different levels
of knowledge about the subject area. In all the educational
activities, there was a strong focus on the importance of
reporting ADRs and an open opportunity whereby individ-
ual health professionals could ask questions and obtain
appropriate practical answers. Within the hospital, intensive
education was provided to complement the Drug and Ther-
apeutics Committee to emphasise the importance of phar-
macovigilance. Here we describe the ADRs detected
following increased education about pharmacovigilance
and drug toxicity.
Methods
Camagüey Province is in the central part of Cuba and
includes the city of Camagüey, smaller towns and rural
areas. It consists of 13 municipal areas and two children’s
hospitals. The main children’s hospital, with 400 beds, is
based in Camagüey, but there is also a smaller children’s
hospital in one of the small towns on the edge of the
province (Florida), with 75 beds. Suspected ADRs are
reported to the Provincial Pharmacovigilance Centre in
Camagüey either personally, by phone or by e-mail. Cama-
güey Province has a population of 783,372, including
183,105 children (0–18 years). Approximately 40% of the
total population lives in the municipality of Camagüey, and
36% of the children of Camagüey Province live in this
municipality.
Over a period of 24 months (January 2009–December
2010), all reported suspected ADR for children were ana-
lysed. Each report contained details of the age and sex of the
patient, name of the health professional notifying the ADR,
healthcare setting, suspected ADR, suspected medicine re-
sponsible for the ADR, reason for prescribing the medica-
tion and time between the ADR and notification. Each
report was analysed in relation to ADR severity and causal-
ity and collated. Each suspected ADR was analysed by a
group of health professionals trained in pharmacovigilance
(the Provincial Pharmacovigilance Group of Experts). Each
report was assessed using the Karch-Lasagna algorithm [9,
10]. For children who experienced more than one ADR, the
clinical impact of the separate ADRs was considered togeth-
er and one severity classification was given. Severity was
classified as severe/moderate/mild [1, 11].
& severe: fatal or potentially life threatening or causing
permanent disability;
& moderate: requiring treatment or prolonging stay in hos-
pital or causing interference with normal daily activities;
& mild: minor reactions that do not require treatment and
do not prolong stay in hospital.
Results
In 2009, there were 161 reports of suspected ADRs in
children received by the Provincial Pharmacovigilance Cen-
tre. In 2010, this increased to 372 reports, making a total of
533 reports over the 2 years. During this 2-year period,
reports were received from nine of the 13 municipalities in
the province. The vast majority (438, 82%) were from
Camagüey Municipality. Following assessment by the Pro-
vincial Pharmacovigilance Group, the majority of ADR
reports in both years (509) were classified as probable.
Thirteen were considered possible, six conditional, one def-
inite and four thought to be unlikely based on what is known
about the drug. The ages of the children for whom ADRs
were reported to be caused by vaccines and medicines are
shown in Table 1. Over the 2 years, received reports in-
volved 281 (53%) girls and 252 (47%) boys. Vaccines were
responsible for more than half of those ADR reports(283,
53%). There was a significant increase in the number of
ADR reports to vaccines in 2010 (from 75 in 2009 to 208 in
Table 1 Ages of children for whom an adverse drug reaction (ADR)
was reported: 2009–2010





n % n % n %
0–1 month 6 2 3 1 9 2
2–11 months 14 6 117 41 131 25
1–2 years 33 13 57 20 90 17
3–5 years 47 19 50 18 97 18
6–10 years 41 16 26 9 67 12
11–17 years 109 44 30 11 139 26
Total 250 100 283 100 533 100
1080 Eur J Clin Pharmacol (2012) 68:1079–10842010) and was associated with the widespread use of A-
H1N1 vaccine. A total of 250 ADR reports were received
for medicines; 86 of these were received in 2009, and 164 in
2010.
The majority of reports sent to the centre over the 2 years
came from primary health care (405, 76%). 128 (24%)
reports came from hospitals, 11 of which were submitted
in 2009 and 117 in 2010. Doctors sent most reports (390,
73%). Other reports were received from pharmacists (82,
15%), registered nurses (48,9 % ) ,n u r s et e c h n i c i a n s( 7 ,
1.3%) and pharmacy technicians (2, 0.4%). In 2010, for
the first time, the provincial centre received four ADR
reports from parents (0.7%). There were 855 suspected
ADRs within the reports (1.6 suspected ADRs per report).
There were 490 suspected ADRs reported following the use
of vaccines. The ten most frequently reported ADRs to
vaccines are shown in Table 2. There were 365 separate
suspected ADRs following the use of medicines, and the ten
most frequently reported ADRs are shown in Table 3.A
total of 58 different medicines were suspected to be respon-
sible for the ADRs in 2009, and ten other medicines were
prescribed concurrently. In 2010, 49 different medicines
were suspected to be responsible for the ADRs, and 19 other
medicines were prescribed concurrently.
The three other groups of medicines associated with a
large number of ADR reports were antibiotics, antihist-
amines and nonopioid analgesics (Table 4). One hundred
and nine reports were received for antibiotics, for a total of
159 suspected ADRs. The antibiotics most frequently asso-
ciated with ADRs were benzylpenicillin (31), amoxicillin
(26), erythromycin (20), azithromycin (19) and cephalexin
(19). Two antihistamines, loratadine (28) and ketotifen (20),
were associated with >76% of the 63 ADRs contained
within 54 reports due to antihistamines. There were 35
reports of ADRs due to nonopioid analgesics, and within
these reports were 50 suspected ADRs. Thirty-two of these
were associated with the use of dipyrone. The most frequent
ADRs following dipyrone were urticaria/angioedema (10),
facial oedema (6), nausea (3) and syncope (3). Twelve
ADRs were associated with the use of nonsteroidal anti-
inflammatory drugs (5 ibuprofen, 3 indomethacin, 2 salicy-
lates and 2 piroxicam) and six due to paracetamol.
The majority of reports received were classified as mild
(367, 69%); 155 (29%) were moderate and ten (2%) were
severe. There was one fatality in association with the use of
ceftriaxone. Vaccines (7) and antibiotics (3) were responsi-
ble for the ten severe ADRs (Tables 5 and 6).
Table 2 Ten most frequently reported adverse drug reactions (ADRs)
to vaccines in children in Camagüey Province, Cuba: 2009–2010
ADR 2009 2010 Combined
n % n % n %
Fever 56 44 157 43 213 43
Rhinitis/cough 0 0 47 13 47 10
Vomiting 6 5 23 6 29 6




10 8 18 5 28 6
Irritability and tearfulness 13 10 4 1 17 4
Diarrhoea 2 2 15 4 17 4
Respiratory tract infection 0 0 15 4 15 3
Headache 0 0 14 4 14 3
Peripheral cyanosis 4 3 5 1 9 2
Others 18 14 55 15 73 15
Total 127 100 363 100 490 100
Table 3 Ten most frequently reported adverse drug reactions (ADRs)
to drugs reported in children in Camagüey Province, Cuba: 2009–2010
ADR 2009 2010 Combined
n % n % n %
Urticaria/angioedema 41 30 64 28 105 29
Drowsiness 3 2 38 17 41 11
Vomiting 11 8 21 9 32 9
Nausea 9 7 8 4 17 5
Oedema 5 4 11 5 16 4
Irritability and tearfulness 4 3 10 4 14 4
Abdominal pain 8 6 6 3 14 4
Dizziness/vertigo 6 4 6 3 12 3
Tachycardia 4 3 6 3 10 3
Asthenia 5 4 5 2 10 3
Others 41 30 53 23 94 26
Total 137 100 228 100 365 100
Table 4 Drug classes and reports of suspected adverse drug reactions
(ADRs)
Medicine 2009 2010 Combined
n (%) n (%) n (%)
Antibiotics 36 42 73 45 109 44
Antihistamines 9 10 45 27 54 22
Analgesics nonopioid 11 13 24 15 35 14
Bronchodilators 6 7 8 5 14 6
Vitamins and minerals 7 8 2 1 9 4
Prokinetic agents 2 2 4 2 6 2
Antiparasitic agents 5 6 0 0 5 2
Corticosteroids 2 2 1 1 3 1
Others 8 9 7 4 15 6
Total 86 100 164 100 250 100
Eur J Clin Pharmacol (2012) 68:1079–1084 1081The clinical impact of the ADR was significant in 60
children in 2009 in that they required emergency care either
in a polyclinic or a hospital. In 2010, a similar number (54)
required emergency care. In 2008, 19 moderate and seven
severe ADRs and 20 children required emergency treatment
in a polyclinic or a hospital [1].
Discussion
Underreporting of ADRs is a significant problem world-
wide. There is significant variation between different
countries in relation to the number of ADRs reported. The
Uppsala Monitoring Centre receives data from national
pharmacovigilance centres of >100 countries. During
2010, the centre received >1 million reports, with New
Zealand submitting the highest number of reports per capita
(1,200 reports per 1 million inhabitants per year) [12]. Cuba
submits the highest number of reports per capita in Latin
America [12].
We previously demonstrated an ADR reporting rate of
634 per 1 million children per year in Cuba [1], which is
considerably higher than the reporting rate from Sweden of
226 per 1 million children per year [2] and Denmark of 222
per 1 million children per year [13]. Following an intensive
educational package, both within the community and the
Children’s Hospital, we managed to significantly increase
the reporting rate of ADRs. The number of reports in Cama-
güey Province per 1 million children per year in 2009 was
879 and in 2010 was 2,031. The number of reports was
considerably higher than the reports received in Cuba na-
tionally in 2009 and 2010: 677 and 1,278 reports per 1
million children per year, respectively. It is important to
recognise that the increased reporting of ADRs detected a
greater proportion of moderate and severe ADRs (31%) than
prior to the educational intervention (21%) [1]. The most
frequently reported ADRs in our study (fever, urticaria and
vomiting) were similar to the most frequently reported
ADRs in a recent paper from the Uppsala Monitoring Cen-
tre, which describes suspected ADRs reported for children
worldwide [14]. The Children’s Hospital in Camagüey is the
main children’s hospital in the province and is a referral
centre for paediatric intensive care, oncology, neurosurgery
and nephrology alongside general paediatrics. It has had a
Drug and Therapeutics Committee (DTC) since 1998 and
since then has been active in promoting more rational use of
medicines [15]. In 2008 and 2009, there were only 12 and
11 reports received from the hospital, respectively. In 2010,
following the interventions, there was a tenfold increase to
117. This had only been possible due to the combined
Table 5 Severe adverse drug
reactions (ADRs) to vaccines:
2009–2010
Year Age Sex Drug ADR Comments
2009 5 months M Pentavalent vaccine Diarrhoea, vomiting, dehydration
resulting in shock
5 months F Pentavalent vaccine Vomiting, fever resulting in shock
8 months F Pentavalent vaccine Deep venous thrombosis Bilateral renal hypoplasia
5 months F Pentavalent vaccine Seizure
7 months M Pentavalent vaccine Seizure
2010 3 years F A-H1N1 vaccine Severe bronchopneumonia resulting
in shock
Epilepsy
3 years M A-H1N1 vaccine Fever, asthenia, vomiting resulting
in shock
Table 6 Severe adverse drug reactions (ADRs) to medicines: 2009–2010
Year Age Sex Drug ADR Comments Onset of ADR
in relation to drug
Indications
2009 1 month F Ceftriaxone Anaphylactic shock Patient died during
the first IV dose
During administration Acute infectious
diarrhoea
4 years F Amoxicillin Seizure Within 24 h Tonsillitis
2010 3 years M Sodium benzyl
penicillin & procaine
benzyl penicillin




Within 1 h Bronchopneumonia
1082 Eur J Clin Pharmacol (2012) 68:1079–1084efforts of all members of the Drug and Therapeutics Com-
mittee emphasising the importance of pharmacovigilance. It
is recognised, however, that this reporting rate is still likely
to be a significant underestimate of the number of ADRs.
Cytotoxic agents and anticonvulsants are recognised as the
group of medicines most likely to be associated with ADRs
in children [5, 16]. Despite the educational intervention,
however, there were no reports of ADRs to cytotoxic agents
and only two for anticonvulsants in 2009 and 2010. ADRs
to cytotoxic agents and anticonvulsants are often severe [5],
and it is important, therefore, that these ADRs are both
suspected and reported. Specific discussions with the health
professionals involved in treating children with malignan-
cies and epilepsy may be beneficial in encouraging the
submission of ADR reports from these two groups of
children.
Reports were received from the majority of the 13
municipalities in the province. There are practical difficul-
ties in communicating the reports of suspected ADRs in a
lower–middle income country. The postal system is unre-
liable, and there are often shortages of forms for suspected
ADRs. Postal reports are therefore less likely from munic-
ipalities outside of the city of Camagüey. Additionally, in
these predominantly rural areas, one is more likely to
experience problems with Internet connections and subse-
quently e-mail reporting, as well as problems of inadequate
signal strength for mobile phones. These problems are
likely to be experienced by other national pharmacovigi-
lance centres operating in low and lower–middle income
countries.
Our study shows the benefit of an educational inter-
vention in relation to pharmacovigilance in children. It is
recognised that the number of reports received (2,031 per
1 million children per year) is, however, still an under-
estimate. In addition, there is a need to improve the
prescribing of medicines. Ceftriaxone is not recommen-
ded in the neonatal period for two reasons: Firstly, it is
highly protein bound, and this may result in the displace-
ment of bilirubin [17]. Secondly, it has been associated
with sudden death in neonates and young infants due to
calcium precipitation following coadministration of
calcium-containing intravenous solutions [18]. The inap-
propriate prescription of ceftriaxone to a neonate empha-
sises the need for greater awareness regarding medicine
toxicity in specific age groups for all professionals in-
volved with children. The large number of ADRs follow-
ing the use of dipyrone also emphasises the need for
more rational prescribing. Because of safety concerns
(especially agranulocytosis and other blood dyscrasias)
regarding dipyrone, the drug is not available in many
countries worldwide [19, 20]. Greater awareness of the
toxicity associated with the use of nonsteroidals, in par-
ticular, dipyrone, in children needs to be emphasised. A
long-term aim of a pharmacovigilance programme is to
ensure medicines are prescribed more rationally and thus
reduce ADRs.
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